These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 21292470)

  • 1. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms.
    Iacono A; Raso GM; Canani RB; Calignano A; Meli R
    J Nutr Biochem; 2011 Aug; 22(8):699-711. PubMed ID: 21292470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders.
    Musso G; Gambino R; Cassader M
    Curr Opin Lipidol; 2010 Feb; 21(1):76-83. PubMed ID: 19915460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.
    Frazier TH; DiBaise JK; McClain CJ
    JPEN J Parenter Enteral Nutr; 2011 Sep; 35(5 Suppl):14S-20S. PubMed ID: 21807932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity and NAFLD: the role of bacteria and microbiota.
    Duseja A; Chawla YK
    Clin Liver Dis; 2014 Feb; 18(1):59-71. PubMed ID: 24274865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probiotics in the treatment of the liver diseases.
    Kirpich IA; McClain CJ
    J Am Coll Nutr; 2012 Feb; 31(1):14-23. PubMed ID: 22661622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease: current and potential therapies.
    Ibrahim MA; Kelleni M; Geddawy A
    Life Sci; 2013 Feb; 92(2):114-8. PubMed ID: 23159641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microecology, obesity, and probiotics.
    Tennyson CA; Friedman G
    Curr Opin Endocrinol Diabetes Obes; 2008 Oct; 15(5):422-7. PubMed ID: 18769213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prebiotics, probiotics and helminths: the 'natural' solution?
    Guarner F
    Dig Dis; 2009; 27(3):412-7. PubMed ID: 19786773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.
    Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
    World J Hepatol; 2015 Mar; 7(3):559-65. PubMed ID: 25848479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
    Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
    Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probiotics and liver disease.
    Sheth AA; Garcia-Tsao G
    J Clin Gastroenterol; 2008 Jul; 42 Suppl 2():S80-4. PubMed ID: 18542037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reshaping the gut microbiota at an early age: functional impact on obesity risk?
    Luoto R; Collado MC; Salminen S; Isolauri E
    Ann Nutr Metab; 2013; 63 Suppl 2():17-26. PubMed ID: 24217033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease.
    Compare D; Coccoli P; Rocco A; Nardone OM; De Maria S; Cartenì M; Nardone G
    Nutr Metab Cardiovasc Dis; 2012 Jun; 22(6):471-6. PubMed ID: 22546554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data.
    Yki-Järvinen H
    Curr Opin Clin Nutr Metab Care; 2010 Nov; 13(6):709-14. PubMed ID: 20842026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance.
    Parnell JA; Raman M; Rioux KP; Reimer RA
    Liver Int; 2012 May; 32(5):701-11. PubMed ID: 22221818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving trends in nonalcoholic fatty liver disease.
    Delgado JS
    Eur J Intern Med; 2008 Mar; 19(2):75-82. PubMed ID: 18249301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota and obesity.
    Scarpellini E; Campanale M; Leone D; Purchiaroni F; Vitale G; Lauritano EC; Gasbarrini A
    Intern Emerg Med; 2010 Oct; 5 Suppl 1():S53-6. PubMed ID: 20865475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.